1627710-50-2 Chemical Properties

Boiling point:

481.1±45.0 °C(Predicted)

Density 

1.257±0.06 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

Soluble in DMSO

form 

crystalline solid

pka

5.86±0.25(Predicted)

color 

White to off-white

InChI

1S/C22H21F2N3O/c1-26-8-10-27(11-9-26)17-4-2-15(3-5-17)18-6-7-25-14-19(18)16-12-20(23)22(28)21(24)13-16/h2-7,12-14,28H,8-11H2,1H3

InChIKey

IKUFKDGKRLMXEX-UHFFFAOYSA-N

SMILES

Fc1c(c(cc(c1)c2cnccc2c3ccc(cc3)N4CCN(CC4)C)F)O

Safety Information

WGK Germany 

WGK 3

HS Code 

2933998090

Storage Class

11 - Combustible Solids

1627710-50-2 Usage And Synthesis

Uses

LJH685 is a selective and potent RSK inhibitor (1). The p90 ribosomal S6 kinase (RSK) family of serine/threonine kinases is linked to various cancers and its substrate phosphorylation is also related to the regulation of cell survival, proliferation, and cell polarity (2).

Biological Activity

ljh685 is a rsk (p90 ribosomal s6 kinase) inhibitor.the p90 ribosomal s6 kinase (rsk) family of serine/threonine kinases is found to be expressed in a variety of cancers and its substrate phosphorylation has been implicated in direct regulation of cell proliferation, cell survival, as well as cell polarity.

in vitro

in a previous study, the structural analysis results confirmed the binding of ljh685 to the rsk2 n-terminal kinase atp-binding site, which suggested that the inhibitor ljh685 adopted an unusual nonplanar conformation that explained its excellent selectivity for rsk family kinases. in addition, ljh685 and it analog lji308 could efficiently inhibit rsk activity in vitro and in cells. moreover, in a subset of examined cell lines, the cellular inhibition of rsk and its phosphorylation of yb1 on ser102 were found to be closely associate with the inhibition of cell growth in an anchorage-independent growth setting [1].

IC 50

6 nm, 5 nm and 4 nm for the biochemical activities of rsk1, rsk2, and rsk3, respectively

References

[1] aronchik i, appleton ba,basham se,crawford k,del rosario m,doyle lv,estacio wf,lan j,lindvall mk,luu ca,ornelas e,venetsanakos e,shafer cm,jefferson ab. novel potent and selective inhibitors of p90 ribosomal s6 kinase reveal the heterogeneity of rsk function in mapk-driven cancers. mol cancer res.2014 may;12(5):803-12.